Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2561MR)

This product GTTS-WQ2561MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Ewing sarcoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2561MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9529MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA J-591
GTTS-WQ5492MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDP 6038
GTTS-WQ1185MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABP 501
GTTS-WQ9928MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KB-004
GTTS-WQ7261MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ3601MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ4544MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ10217MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LFB-R593
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW